JP2025506515A5 - - Google Patents

Info

Publication number
JP2025506515A5
JP2025506515A5 JP2024547849A JP2024547849A JP2025506515A5 JP 2025506515 A5 JP2025506515 A5 JP 2025506515A5 JP 2024547849 A JP2024547849 A JP 2024547849A JP 2024547849 A JP2024547849 A JP 2024547849A JP 2025506515 A5 JP2025506515 A5 JP 2025506515A5
Authority
JP
Japan
Prior art keywords
domain
receptor
antigen
tgfβr
tim3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024547849A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025506515A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/062475 external-priority patent/WO2023158978A2/en
Publication of JP2025506515A publication Critical patent/JP2025506515A/ja
Publication of JP2025506515A5 publication Critical patent/JP2025506515A5/ja
Pending legal-status Critical Current

Links

JP2024547849A 2022-02-15 2023-02-13 血中のキメラ抗原受容体細胞のブースト Pending JP2025506515A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263310355P 2022-02-15 2022-02-15
US63/310,355 2022-02-15
PCT/US2023/062475 WO2023158978A2 (en) 2022-02-15 2023-02-13 Boosting chimeric antigen receptor cells in the blood

Publications (2)

Publication Number Publication Date
JP2025506515A JP2025506515A (ja) 2025-03-11
JP2025506515A5 true JP2025506515A5 (cg-RX-API-DMAC7.html) 2026-02-17

Family

ID=87578966

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024547849A Pending JP2025506515A (ja) 2022-02-15 2023-02-13 血中のキメラ抗原受容体細胞のブースト

Country Status (11)

Country Link
US (1) US20250177442A1 (cg-RX-API-DMAC7.html)
EP (1) EP4479537A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025506515A (cg-RX-API-DMAC7.html)
KR (1) KR20240151812A (cg-RX-API-DMAC7.html)
CN (1) CN118946663A (cg-RX-API-DMAC7.html)
AU (1) AU2023220999A1 (cg-RX-API-DMAC7.html)
CA (1) CA3249176A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024012103A2 (cg-RX-API-DMAC7.html)
IL (1) IL314427A (cg-RX-API-DMAC7.html)
MX (1) MX2024009987A (cg-RX-API-DMAC7.html)
WO (1) WO2023158978A2 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025176860A1 (en) 2024-02-23 2025-08-28 Charité - Universitätsmedizin Berlin Körperschaft des öffentlichen Rechts Dual chimeric antigen receptor construct targeting cea and epcam

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10829735B2 (en) * 2015-07-21 2020-11-10 The Trustees Of The University Of Pennsylvania Methods for improving the efficacy and expansion of immune cells
SG11201807489PA (en) * 2016-03-04 2018-09-27 Novartis Ag Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
JP7467117B2 (ja) * 2016-10-07 2024-04-15 ノバルティス アーゲー 癌の治療のためのキメラ抗原受容体
US11242389B2 (en) * 2018-09-26 2022-02-08 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-CD19/CD22 immunotherapy
WO2022007650A1 (zh) * 2020-07-06 2022-01-13 四川科伦博泰生物医药股份有限公司 靶向bcma和cd19的嵌合抗原受体car或car构建体及其应用

Similar Documents

Publication Publication Date Title
US12570743B2 (en) BCMA-targeting engineered immune cell and use thereof
US20190023764A1 (en) Car having replicated binding motifs in a co-stimulatory domain
Kershaw et al. Gene-engineered T cells for cancer therapy
JP2025183279A (ja) Bcmaを標的とする操作された免疫細胞及びその使用
JP2015527070A5 (cg-RX-API-DMAC7.html)
US11725053B2 (en) Chimeric antigen receptors comprising a human transferrin epitope sequence
RU2015109631A (ru) Способ и композиции для клеточной иммунотерапии
JP2021519580A5 (cg-RX-API-DMAC7.html)
RU2018105963A (ru) Антитело против глипикана-3 и его применение
JP2019513347A5 (cg-RX-API-DMAC7.html)
EP3578570A1 (en) Multifunctional protein
CN109789164B (zh) 具有gitr胞内结构域作为共刺激结构域的嵌合抗原受体
JP2024534471A5 (cg-RX-API-DMAC7.html)
JP2021532742A5 (cg-RX-API-DMAC7.html)
WO2022199125A1 (zh) 一种自分泌IL-15与anti-PD1融合蛋白的免疫细胞
TWI797610B (zh) 人源化cd19抗體及其應用
HK1255208A1 (zh) 作为用於嵌合抗原受体(car)疗法的t细胞来源的骨髓浸润淋巴细胞(mil)
JP2025161810A (ja) Il-1スーパーファミリーのサイトカインの空間時間的に制限された活性が武装化された免疫応答性細胞
KR20180083868A (ko) 종양 형질도입용 조성물 및 방법
JP2025513626A (ja) Ciita遺伝子がノックアウトされた操作された免疫細胞及びその用途
JP2023503840A5 (cg-RX-API-DMAC7.html)
CN117187185A (zh) 一种工程化免疫细胞及其用途
Hosseini et al. Preclinical studies of chimeric antigen receptor-modified natural killer cells in cancer immunotherapy: a review
WO2024210072A1 (ja) キメラタンパク質、核酸、ベクター、t細胞又はnk細胞、医薬組成物、組み合わせ物、組み合わせ医薬、及び標的抗原結合タンパク質
HK40110123A (en) Engineered immune cell targeting bcma and use thereof